Wuhan Thalys Med Tech Co Ltd (603716) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.052x

Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥54.57 Million ≈ $7.99 Million USD) by net assets (CN¥1.05 Billion ≈ $154.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 603716 net asset quality score to measure how much of total assets are equity-financed.

Wuhan Thalys Med Tech Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Wuhan Thalys Med Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Wuhan Thalys Med Tech Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Wuhan Thalys Med Tech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Log-In Logística Intermodal S.A SA:LOGN3	0.056x
Medprin Regenerative Medical Technologies Co. Ltd. SHE:301033	N/A
Bar Harbor Bankshares Inc NYSE MKT:BHB	0.009x
Shenzhen CDL Precision Technology Co Ltd SHE:300686	-0.009x
CCP Contact Probe Co Ltd TWO:6217	-0.031x
BTQ Technologies Corp. NEO:BTQ	-0.343x
Sharda Motor Industries Limited NSE:SHARDAMOTR	0.127x
H&R Century Union Corp SHE:000892	-0.020x

Annual Cash Flow Conversion Efficiency for Wuhan Thalys Med Tech Co Ltd (2011–2025)

The table below shows the annual cash flow conversion efficiency of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Wuhan Thalys Med Tech Co Ltd stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥904.49 Million ≈ $132.35 Million	CN¥-37.75 Million ≈ $-5.52 Million	-0.042x	-140.32%
2024-12-31	CN¥962.04 Million ≈ $140.78 Million	CN¥99.60 Million ≈ $14.57 Million	0.104x	+8.12%
2023-12-31	CN¥1.31 Billion ≈ $192.38 Million	CN¥125.89 Million ≈ $18.42 Million	0.096x	+409.71%
2022-12-31	CN¥1.50 Billion ≈ $219.05 Million	CN¥28.12 Million ≈ $4.12 Million	0.019x	+124.52%
2021-12-31	CN¥1.74 Billion ≈ $255.04 Million	CN¥-133.52 Million ≈ $-19.54 Million	-0.077x	-1488.68%
2020-12-31	CN¥1.80 Billion ≈ $263.77 Million	CN¥9.94 Million ≈ $1.46 Million	0.006x	-90.48%
2019-12-31	CN¥1.62 Billion ≈ $237.21 Million	CN¥93.92 Million ≈ $13.74 Million	0.058x	+247.56%
2018-12-31	CN¥1.63 Billion ≈ $237.88 Million	CN¥-63.83 Million ≈ $-9.34 Million	-0.039x	+37.69%
2017-12-31	CN¥1.00 Billion ≈ $146.88 Million	CN¥-63.25 Million ≈ $-9.26 Million	-0.063x	-218.21%
2016-12-31	CN¥859.29 Million ≈ $125.74 Million	CN¥-17.02 Million ≈ $-2.49 Million	-0.020x	-120.20%
2015-12-31	CN¥470.30 Million ≈ $68.82 Million	CN¥46.11 Million ≈ $6.75 Million	0.098x	+32.39%
2014-12-31	CN¥405.99 Million ≈ $59.41 Million	CN¥30.07 Million ≈ $4.40 Million	0.074x	-21.25%
2013-12-31	CN¥345.97 Million ≈ $50.63 Million	CN¥32.54 Million ≈ $4.76 Million	0.094x	+933.02%
2012-12-31	CN¥296.50 Million ≈ $43.39 Million	CN¥2.70 Million ≈ $394.98K	0.009x	+109.55%
2011-12-31	CN¥253.90 Million ≈ $37.15 Million	CN¥-24.22 Million ≈ $-3.54 Million	-0.095x	--

About Wuhan Thalys Med Tech Co Ltd

SHG:603716 China Diagnostics & Research

Market Cap

$580.19 Million

CN¥3.96 Billion CNY

Market Cap Rank

#11471 Global

#3223 in China

Share Price

CN¥17.56

Change (1 day)

+4.59%

52-Week Range

CN¥13.40 - CN¥36.40

All Time High

CN¥45.48